The greater antiproteinuric and potentially nephroprotective effects of dual ETAR and AT1R inhibition as compared with losartan alone corresponds to clinical evidence accumulated over the past decade both in patients with diabetic nephropathy [19, 27, 28] as well as in patients with nondiabetic glomerular diseases, including those with IgAN. This evidence concerns the gene EDNRA and glomerular disorder.